More recently, Patterson et al[66] demonstrated that treatment of neuroblastoma cells with the MDM2 small molecule inhibitor, Nutlin-3a, significantly reduces angiogenesis, which is also consistent with our findings given that MYCN is a positive transcriptional regulator of MDM2. Thus, miR-34a up-regulation in tumors has an anti-angiogenic effect potentially mediated through direct inhibition of MYCN. Here, MYCN is linked to neuroblastoma.